Therefore, it can be suggested that SHP2 activation is upstream in the signaling pathway involved in ODN-induced Raptor downregulation and mitochondrial dysfunction, eventually enhancing sensitivity to anti-cancer drugs. This evidence concerns the gene PTPN11 and cancer.